Elanco Animal Health INC

Elanco Animal Health Incorporated reports the successful election of directors and ratification of auditors at its 2026 annual meeting.

Elanco Animal Health reported strong first quarter 2026 results, with revenue up 15% year-over-year, and raised its full-year financial guidance.

Elanco Animal Health reported strong fourth quarter and full year 2025 results, exceeding innovation revenue targets and providing optimistic 2026 guidance in line with its Investor Day outlook.

Elanco Animal Health presented its strategy for consistent growth, innovation, and cash generation at the 44th Annual J.P. Morgan Healthcare Conference, reaffirming its 2025 outlook and projecting significant future expansion.

Elanco Animal Health Inc. announced a restructuring plan, a new three-year financial outlook, and significant innovation pipeline updates at its Investor Day.

Elanco Animal Health reported robust third-quarter 2025 results, exceeding expectations and prompting an upward revision of its full-year financial guidance and innovation targets.

Elanco Animal Health Incorporated announced its first quarter 2026 financial results, showcasing a 15% increase in revenue and a net income of $57 million.

Elanco Animal Health reported a net loss of $34 million in Q3 2025, a significant decline from the prior year's profit, despite a 10% revenue increase driven by new product introductions.

Elanco Animal Health reported a significant turnaround in Q2 2025, achieving net income of $11 million compared to a $50 million loss in the prior year, driven by strong Pet Health sales and reduced special charges.

Elanco Animal Health's Q1 2025 results show a slight revenue decrease but improved net income, driven by cost management and strategic divestitures.

Elanco Animal Health's Q3 2024 results show a net income of $364 million, driven by a significant gain from the divestiture of its aqua business, despite a slight revenue decrease.

Elanco Animal Health's second-quarter results show a net loss, impacted by restructuring and asset impairments, while revenue saw a modest increase.

Elanco Animal Health reported a net loss of $232 million in 2025, driven by significant restructuring charges and asset impairments, despite revenue growth and new product launches.

Elanco Animal Health's 2024 results highlight strategic shifts, including the divestiture of its aqua business and advancements in its product portfolio.

Elanco Animal Health Incorporated released its full-year 2023 financial results, highlighting a year of strategic acquisitions, restructuring efforts, and a significant goodwill impairment charge, while navigating a complex global market and regulatory environment.

Jeffrey N Simmons, PRESIDENT, CEO AND DIRECTOR and a Director of Elanco Animal Health Inc, received 113 shares of common stock on July 24, 2026.

Rajeev A. Modi, SEE REMARKS of Elanco Animal Health Inc, received 59 shares of common stock on July 24, 2026.

Robert M Vanhimbergen, EVP and CFO of Elanco Animal Health Inc, received 8 shares of common stock on July 24, 2026.

Jeffrey N Simmons, PRESIDENT, CEO AND DIRECTOR and a Director of Elanco Animal Health Inc, received 114 shares of common stock on July 10, 2026.

Rajeev A. Modi, SEE REMARKS of Elanco Animal Health Inc, received 60 shares of common stock on July 10, 2026.

Elanco Animal Health Inc. reports a transaction by its EVP and CFO, Robert M. VanHimbergen, involving the acquisition of common stock.

Elanco Animal Health Incorporated announced its 2026 Annual Meeting of Shareholders, detailing director nominations, executive compensation, and auditor ratification.

Elanco Animal Health Incorporated announces its 2025 Annual Meeting of Shareholders to be held virtually on May 16, 2025.

Elanco Animal Health reports strong 2024 performance and outlines strategic priorities for continued growth in 2025, while also announcing board changes.

Elanco Animal Health Incorporated has filed a definitive proxy statement with the SEC.

Elanco is asking shareholders to approve key governance changes, including declassifying the board and adopting a majority vote standard for director elections, while also preparing for a leadership transition with a new Board Chairman.

Elanco responds to Ancora Holdings Group's press release, emphasizing its commitment to its strategy, recent stock performance, and continued shareholder engagement.

Dimensional Fund Advisors LP has disclosed a beneficial ownership of 5.1% of Elanco Animal Health Inc.'s common stock as of June 30, 2026.

Dodge & Cox has reported a beneficial ownership of 13.9% in Elanco Animal Health Incorporated as of March 31, 2026, holding 68,944,100 shares.

PrimeCap Management Co/CA/ has reported a beneficial ownership of 9.22% in Elanco Animal Health Incorporated as of March 31, 2026.

Vanguard Capital Management has filed a Schedule 13G reporting a 5.25% beneficial ownership stake in Elanco Animal Health Inc.

Dimensional Fund Advisors LP has disclosed a beneficial ownership of 4.9% of Elanco Animal Health Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Elanco Animal Health Inc. following an internal realignment.